OBM Geriatrics

(ISSN 2638-1311)

OBM Geriatrics is an Open Access journal published quarterly online by LIDSEN Publishing Inc. The journal takes the premise that innovative approaches – including gene therapy, cell therapy, and epigenetic modulation – will result in clinical interventions that alter the fundamental pathology and the clinical course of age-related human diseases. We will give strong preference to papers that emphasize an alteration (or a potential alteration) in the fundamental disease course of Alzheimer’s disease, vascular aging diseases, osteoarthritis, osteoporosis, skin aging, immune senescence, and other age-related diseases.

Geriatric medicine is now entering a unique point in history, where the focus will no longer be on palliative, ameliorative, or social aspects of care for age-related disease, but will be capable of stopping, preventing, and reversing major disease constellations that have heretofore been entirely resistant to interventions based on “small molecular” pharmacological approaches. With the changing emphasis from genetic to epigenetic understandings of pathology (including telomere biology), with the use of gene delivery systems (including viral delivery systems), and with the use of cell-based therapies (including stem cell therapies), a fatalistic view of age-related disease is no longer a reasonable clinical default nor an appropriate clinical research paradigm.

Precedence will be given to papers describing fundamental interventions, including interventions that affect cell senescence, patterns of gene expression, telomere biology, stem cell biology, and other innovative, 21st century interventions, especially if the focus is on clinical applications, ongoing clinical trials, or animal trials preparatory to phase 1 human clinical trials.

Papers must be clear and concise, but detailed data is strongly encouraged. The journal publishes research articles, reviews, communications and technical notes. There is no restriction on the length of the papers and we encourage scientists to publish their results in as much detail as possible.

Indexing: DOAJ-Directory of Open Access Journals.

Archiving: full-text archived in CLOCKSS.

Rapid publication: manuscripts are undertaken in 6 days from acceptance to publication (median values for papers published in this journal in the first half of 2020, 1-2 days of FREE language polishing time is also included in this period). A first decision provided to authors of manuscripts submitted to this journal are approximately 3.3 weeks (median values) after submission.

Current Issue: 2020  Archive: 2019 2018 2017

Special Issue

Research on Neurodegenerative Diseases

Submission Deadline: December 15, 2020 (Open) Submit Now

Guest Editor

Douglas G. Walker, PhD

Special Contract Professor, Molecular Neuroscience Research Center, Shiga University of Medical Science, Otsu 520-2192, Japan

E-Mail

Research Interests: Alzheimer’s disease; Parkinson’s disease; neurodegenerative diseases

About This Topic

It is with pleasure that we are inviting submissions for this special issue entitled “Research on Neurodegenerative Diseases”. This is a broad title but it is timely for researchers to discuss their hypotheses, results and reviews on the current state of the field with emphasis on new research approaches. Neurodegenerative diseases remain one of the most significant causes of morbidity and mortality, particularly in the aging populations. Despite years of biological and medical research, there are still an unfilled need for new and effective therapies for diseases such as Alzheimer’s disease, Parkinson’s disease, Dementia with Lewy bodies, stroke, vascular dementia and multiple sclerosis. It is timely to consider whether current targets such as amyloid beta, tau, inflammation, alpha synuclein amongst others need to be reconsidered, and whether immunotherapy is likely to be effective. With the huge increase in RNA expression and single nucleotide polymorphism data, consideration how these data have advanced therapy development is also warranted. Similarly, there is a need to consider how the use of induced pluripotent stem cells has advanced our understanding of neurodegeneration.

Newsletter

TOP